RETHINK-ALZ
Simufilam 100 mg for Mild to Moderate Alzheimer’s Disease
Past Studies
X-TOLE: XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy, with an Open-Label Extension
A clinical research study is underway for people with focal epilepsy currently taking 1-3 anti-epileptic drugs that are still experiencing frequent seizures. Three doses of investigational drug are being studied and some participants will be assigned placebo. All participants will receive active study on the extension study.
PIONEER T3D: Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate Alzheimer’s Disease Subjects
PIONEER T3D: Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate Alzheimer’s Disease Subjects Inclusion Criteria Age 55-90 years Have a reliable study partner, an identified adult who has sufficient contact to knowledgeably report on the subject’s daily cognition, function, behavior, safety, compliance and adherence. Have a clinical diagnosis of mild-to-moderate AD Visual and
TRAILBLAZER-2: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease
The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer’s disease.
Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI3)
The Alzheimer’s Disease Neuroimaging Initiative (also known as ADNI) is a historic study of brain aging looking to help change the future for this disease.
Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI3) Read More »